Successful treatment of COVID-19 with colchicine in a kidney transplant recipient

QJM. 2021 May 19;114(3):197-199. doi: 10.1093/qjmed/hcaa323.

Authors

S Nozato¹, A Ito¹, K Terashima², Y Nozato³, Y Yoshii², K Seki¹, R Yoshimoto¹, A Morishima², K Sakaguchi², M Kitano¹

Affiliations

¹ Division of Immunology and Rheumatology, Sumitomo Hospital, 5-3-20 Nakanosima, Kita-ku, Osaka 530-0005, Japan.
² Kidney Center, Sumitomo Hospital, 5-3-20 Nakanosima, Kita-ku, Osaka 530-0005, Japan.
³ Department of Geriatric and General Medicine, Osaka University Graduate School Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan.

No abstract available

Publication types

Case Reports

MeSH terms

Adult
COVID-19 Drug Treatment*
Colchicine / therapeutic use*
Humans
Immunocompromised Host
Kidney Transplantation*
Male
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / virology
SARS-CoV-2
Transplant Recipients

Substances

Colchicine